Cite
HARVARD Citation
Schindler, U. et al. (n.d.). AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, leads to greater immune activation and reduced tumor growth when combined with chemotherapy. European journal of cancer. pp. S14-S15. [Online].